Future investigation using pharmacologic or non‐pharmacologic NF‐κB inhibitors, such as dietary analogues in in vivo models may reveal the capability of NF‐κB inhibition in preventing or reversing the acidic bile‐induced deregulations of cancer‐related miR‐21, miR‐21, miR‐155, ‐192, 34a, ‐375 and ‐451a in treated hypopharyngeal mucosa. Here, NFKB1 is linked to cancer.